Cancer and Blood Disorders

Show Only Open Trials
1.

A single-arm, open-label Phase 2a study to evaluate the efficacy and safety of Copanlisib monotherapy in patients with relapsed or refractory mantle cell lymphoma (MCL), who failed ibrutinib treatment or were unable to tolerate ibrutinib

  • Study Status: Open to Enrollment
  • Sponsor: Bayer Corporation
  • Disease Status and/or Stage: Mantle Cell Lymphoma
  • Protocol ID: WCMC IRB #1505016220; Sponsor Protocol #17120; ClinicalTrials.gov #NCT2455297
2.

A Phase 2 Trial to Evaluate the Efficacy of AZD6094 (HMPL 504) in Patients with Papillary Renal Cell Carcinoma (PRCC)

  • Study Status: Open to Enrollment
  • Sponsor: AstraZeneca
  • Disease Status and/or Stage: Papillary Renal Cell Carcinoma (Kidney Cancer)
  • Protocol ID: WCMC IRB #1505016203; Sponsor Protocol #D5082C00002; ClinicalTrials.gov # NCT02127710
3.

Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction (GEJ) Adenocarcinoma

  • Study Status: Open to Enrollment
  • Sponsor: Boston Biomedical, Inc.
  • Disease Status and/or Stage: Stomach and Gastroesophageal (GEJ) Junction Cancer
  • Protocol ID: WCMC IRB #1404015034; Sponsor Protocol #BBI608-336; Clinicaltrials.gov #NCT02178956
4.

Phase 3 Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer

  • Study Status: Open to Enrollment
  • Sponsor: XBiotech USA, Inc.
  • Disease Status and/or Stage: Metastatic Colorectal Cancer
  • Protocol ID: WCMC IRB #1504016139; Sponsor Protocol #2012-PT023
5.

Phase 1b Dose-escalation Study Evaluating Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Subjects with Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
  • Protocol ID: WCMC IRB #1502015899; Sponsor Protocol #GS-US-325-1348; Clinicaltrials.gov #NCT02258555
6.

A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects with B-cell Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: Acerta Pharma
  • Disease Status and/or Stage: Diagnosis of non-GCB DLBCL, MCL, FL, WM, or CLL/SLL
  • Protocol ID: WCMC IRB #1411015661; Sponsor Protocol #ACE-LY-001; Clinicaltrials.gov #NCT02328014
7.

Phase 1/2 Study to Determine Safety, Pharmacokinetics and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Rituximab and CC-122 and Ibrutinib in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Celgene Corporation
  • Disease Status and/or Stage: Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Protocol ID: WCMC IRG #1502015869; Sponsor Protocol #CC-122-CLL-001; Clinicaltrials.gov #NCT02406742
8.

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [RAINFALL]

  • Study Status: Open to Enrollment
  • Sponsor: Eli Lilly and Company
  • Disease Status and/or Stage: Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
  • Protocol ID: WCMC IRB #1411015701; Sponsor Protocol #I4T-MC-JVCU
9.

Phase 2 Open, Non-randomized Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Memorial Sloan-Kettering Cancer Center & Bayer Corporation
  • Disease Status and/or Stage: Metastatic Prostate Cancer
  • Protocol ID: WCMC IRB #1410015538; Sponsor Protocol #14-098 / PCCTC LOI: c13-124; Clinicaltrials.gov #NCT0227805
10.

Developing a measure of treatment and illness understanding in patients with indolent lymphomas

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Lymphoma
  • Protocol ID: WCMC IRB #1502015950
11.

Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Solid Tumors (pancreatic, lung, esophagogastric 1)
  • Protocol ID: WCMC IRB #1309014284; Sponsor Protocol #GS-US-296-0101
12.

Phase 3, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

  • Study Status: Open to Enrollment
  • Sponsor: AstraZeneca
  • Disease Status and/or Stage: Metastatic Pancreatic Cancer
  • Protocol ID: WCMC IRB #1412015766; Sponsor Protocol #D081FC00001
13.

Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma

  • Study Status: Open to Enrollment
  • Sponsor: Eli Lilly and Company
  • Disease Status and/or Stage: Hepatocellular Carcinoma (liver cancer)
  • Protocol ID: WCMC IRB #1202012167; Sponsor Protocol #H9H-MC-JBAK; Clinicaltrials.gov #NCT01246986
14.

Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-cell Receptor Signaling Pathway Inhibitor Therapy

  • Study Status: Open to Enrollment
  • Sponsor: AbbVie
  • Disease Status and/or Stage: Chronic Lymphocytic Leukemia (CLL)
  • Protocol ID: WCMC IRB #1411015655; Sponsor Protocol #M14-032; ClinicalTrials.gov #NCT02141282
15.

A Phase 2 Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)

  • Study Status: Open to Enrollment
  • Sponsor: Southwest Oncology Group
  • Disease Status and/or Stage: Diffuse Large B-cell Lymphoma
  • Protocol ID: WCMC IRB #1304013857; Sponsor Protocol #S1001; Clinicaltrials.gov #NCT01359592
16.

An exploratory randomized phase 2 multicenter trial of abiraterone acetate with or without cabazitaxel in treatment of metastatic castration resistant prostate cancer

  • Study Status: Open to Enrollment
  • Sponsor: Sanofi Aventis, Memorial Sloan Kettering Cancer Center
  • Disease Status and/or Stage: Metastatic Castration Resistant Prostate Cancer
  • Protocol ID: WCMC IRB #1411015711; Sponsor Protocol #14-046; Clinicaltrials.gov #NCT02218606
17.

Phase 2, Randomized, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Clovis Oncology
  • Disease Status and/or Stage: FGFR1- or 11q Amplified Metastatic Breast Cancer
  • Protocol ID: WCMC IRB #1407015311; Sponsor Protocol #CO-3810-025; Clinicaltrials.gov #NCT02202746
18.

Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb Research & Development
  • Disease Status and/or Stage: Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphomas
  • Protocol ID: WCMC IRB #1404015005; Sponsor Protocol #CA224022
19.

Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Patients with Refractory and/or Relapsed Richter's Transformation

  • Study Status: Open to Enrollment
  • Sponsor: Karyopharm Therapeutics
  • Disease Status and/or Stage: Refractory and/or Relapsed Richter's Transformation
  • Protocol ID: WCMC IRB #1408015390; Sponsor Protocol #KCP-330-010; Clinicaltrials.gov #NCT02138786
20.

Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  • Study Status: Open to Enrollment
  • Sponsor: Karyopharm
  • Disease Status and/or Stage: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • Protocol ID: WCMC IRB #1409015502; Sponsor Protocol #KPT-330-009
21.

Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

  • Study Status: Open to Enrollment
  • Sponsor: Gilead Sciences, Inc.
  • Disease Status and/or Stage: Chronic Lymphocytic Leukemia
  • Protocol ID: WCMC IRB #1407015277; Sponsor Protocol #GS-US-312-0133; ClinicalTrials.gov #NCT02044822
22.

Phase 3, double-blind randomized study to compare the efficacy and safety of rituximab plus lenalidomide (cc-5013) versus rituximab plus placebo in subjects with relapsed/refractory indolent lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Celgene Corporation
  • Disease Status and/or Stage: Relapsed/Refractory Indolent Lymphoma
  • Protocol ID: WCMC IRB #1403014923; Sponsor Protocol #CC-5013-NHL-007
23.

Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Acerta Pharma BV
  • Disease Status and/or Stage: Mantle Cell Lymphoma
  • Protocol ID: WCMC IRB #1409015487; Sponsor Protocol #ACE-LY-004
24.

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant for subjects with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: TetraLogics Pharmaceuticals
  • Disease Status and/or Stage: Myelodysplatic Syndrome or Chronic Myelomoncytic Leukemia
  • Protocol ID: WCMC IRB #1409015465; Sponsor Protocol #TL32711-RAN-0094-PTL
25.

An Open-label, Phase 1b Study of ACP-196 in Subjects with Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Acerta Pharma BV
  • Disease Status and/or Stage: Follicular Lymphoma
  • Protocol ID: WCMC IRB #1408015384; Sponsor Protocol #ACE-LY-003
26.

Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase 3 Study evaluating the efficacy & safety of pertuzumab in combination with trastuzumab & chemotherapy in patients with HER2-positive metastatic gastro esophageal junction and gastric cancer

  • Study Status: Open to Enrollment
  • Sponsor: Genentech
  • Disease Status and/or Stage: HER2-positive Advanced Cancer of the Stomach or Junction of the tomach and esophagus
  • Protocol ID: WCMC IRB #1410015525; Sponsor Protocol #BO25114
27.

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: classical Hodgkin Lymphoma
  • Protocol ID: WCMC IRB #1406015182; Sponsor Protocol #CA209-205; ClinicalTrials.gov #NCT02181738
28.

Study of Nivolumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Diffuse Large B-Cell Lymphoma
  • Protocol ID: WCMC IRB #1402014779; Sponsor Protocol #CA209-139; ClinicalTrials.gov #NCT02038933
29.

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom's Macroglobulinemia

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics, Inc.
  • Disease Status and/or Stage: Previously Treated Waldenstrom's Macroglobulinemia
  • Protocol ID: WCMC IRB #1404015017; Sponsor Protocol #PCYC-1127; ClinicalTrials.gov #NCT02165397
30.

Phase 1b Multicenter Dose-finding and Safety Study of GDC-0199 and Obinutuzumab in Patients with Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Genentech
  • Disease Status and/or Stage: Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
  • Protocol ID: WCMC IRB #1309014345; Sponsor Protocol #GP28331; ClinicalTrials.gov #NCT01685892
31.

Phase 1, Multicenter, Open-label, dose escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Acerta Pharma
  • Disease Status and/or Stage: Chronic Lymphocytic Leukemia
  • Protocol ID: WCMC IRB #1311014537; Sponsor Protocol #ACE-CL-001; ClinicalTrials.gov #NCT02029443
32.

Phase 2 Open-Label Study of the Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion

  • Study Status: Open to Enrollment
  • Sponsor: AbbVie
  • Disease Status and/or Stage: Relapsed or Refractory Chronic Lymphocytic Leukemia
  • Protocol ID: WCMC IRB #1308014231; Sponsor Protocol #M13-982; ClinicalTrials.gov #NCT01889186
33.

Rituximab, Bendamustine Hydrochloride, and Bortezomib followed by Rituximab and Lenalidomide in treating older patients with previously untreated Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Eastern Cooperative Oncology Group
  • Disease Status and/or Stage: Mantle Cell Lymphoma
  • Protocol ID: WCMC IRB #1207012759; Sponsor Protocol #ECOG-E1411; ClinicalTrials.gov #NCT01415752
34.

Randomized Multi-center Pivotal Study of CDX-011 in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The "METRIC" Study)

  • Study Status: Open to Enrollment
  • Sponsor: Celldex Therapeutics, Inc.
  • Disease Status and/or Stage: Triple Negative Breast Cancer
  • Protocol ID: WCMC IRB #1403014844; Sponsor Protocol #CDX011-04
35.

Randomized, Open Label, Phase 2 Study of Selinexor (KPT-330) vs Physician's Choice in Patients Greater Than or Equal to 60 Years Old w/Relapsed/Refractory AML who are Ineligible for Intensive Chemo and/or Transplant

  • Study Status: Open to Enrollment
  • Sponsor: Kayorpham Therapeutics, Inc.
  • Disease Status and/or Stage: Acute Myeloid Leukemia
  • Protocol ID: WCMC IRB #1405015140; Sponsor Protocol #KCP-330-008; ClinicalTrials.gov #NCT02088541
36.

Dose Escalation and Cohort Expansion Study of TEN-010 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

  • Study Status: Open to Enrollment
  • Sponsor: Tensha Therapeutics, Inc.
  • Disease Status and/or Stage: Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
  • Protocol ID: WCMC IRB #1409015842; Sponsor Protocol #TEN-010-004
37.

ANCHOR: Anal Cancer/HSIL Outcomes Research Study

  • Study Status: Open to Enrollment
  • Sponsor: National Cancer Institute Office of HIV and AIDS Malignancy (OHAM)
  • Disease Status and/or Stage: HIV Positive; Anal Cancer
  • Protocol ID: WCMC IRB #1407015335; Sponsor Protocol #A01; ClinicalTrials.gov #NCT02135419
38.

A Pilot Study to Evaluate Immunologic Biomarkers of Treatment Response and Disease Activity in Hodgkin Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: New York University Cancer Institute
  • Disease Status and/or Stage: Hodgkin Lymphoma
  • Protocol ID: WCMC IRB #1305013885; Sponsor Protocol #S12-02437
39.

A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Relapsed or Refractory Follicular Lymphoma
  • Protocol ID: WCMC IRB #1402014780; Sponsor Protocol #CA209-140; ClinicalTrials.gov #NCT02038946
40.

Multicenter Phase 2 Study of Single-Agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Array BioPharma Inc.
  • Disease Status and/or Stage: Advanced Multiple Myeloma
  • Protocol ID: WCMC IRB #1404014976; Sponsor Protocol #520-215
41.

Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: Calithera Biosciences
  • Disease Status and/or Stage: Non-Hodgkins Lymphoma; Waldenstrom's Macroglobulinemia; Multple Myeloma; Diffuse Large B-Cell Lymphoma; B-Cell NHL
  • Protocol ID: WCMC IRB #1404014998; Sponsor Protocol #CX-839-002
42.

An Open Label, Phase 1b, Study of ACP-196 in Subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)

  • Study Status: Open to Enrollment
  • Sponsor: Acerta Pharma BV
  • Disease Status and/or Stage: Diffuse Large B-cell Lymphoma
  • Protocol ID: WCMC IRB #1407015285; Sponsor Protocol #ACE-LY-002
43.

An Extension Study to Investigate the Safety and Durability of Clinical Activity of CAL-101 in Patients with Hematologic Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: Gilead Sciences
  • Disease Status and/or Stage: Hematologic (blood) malignancies
  • Protocol ID: WCMC IRB #1003010934; Sponsor Protocol #101-99; Clinicaltrials.gov # NCT01090414
44.

Open-label, Phase 1b Study of ACP 196 in Subjects with Waldenstrom Macroglobulinemia

  • Study Status: Open to Enrollment
  • Sponsor: Acerta Pharma
  • Disease Status and/or Stage: Waldenstrom Macroglobulinemia
  • Protocol ID: WCMC IRB #1407015279; Sponsor Protocol #ACE-WM-001; ClinicalTrials.gov #NCT02180724
45.

Long-term Safety Study Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B cell Lymphoma and Chronic Lymphocytic Leukemia (PCYC-1103)

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: B-cell lymphoma & chronic lymphocytic leukemia
  • Protocol ID: WCMC IRB #1102011519; Sponsor Protocol #PCYC-1103-CA; Clinicaltrials.gov #NCT01109069
46.

A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously enrolled in Study IPI-145-07

  • Study Status: Open to Enrollment
  • Sponsor: Infinity Pharmaceuticals, Inc.
  • Disease Status and/or Stage: Chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Protocol ID: WCMC IRB #1312014602; Sponsor Protocol #IPI-145-12; Clinicaltrials.gov #NCT02004522
47.

Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Infinity Pharmaceuticals, Inc.
  • Disease Status and/or Stage: Relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Protocol ID: WCMC IRB #1312014601; Sponsor Protocol #IPI-145-07; Clincaltrials.gov #NCT02004522
48.

Phase 1, Multicenter, Open-label and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Acerta Pharma
  • Disease Status and/or Stage: Chronic lymphocytic leukemia
  • Protocol ID: WCMC IRB #1311014537; Sponsor Protocol #ACE-CL-001; Clinicaltrials.gov #NCT02029443
49.

Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium Pharmaceuticals
  • Disease Status and/or Stage: Advanced classical hodgkin lymphoma
  • Protocol ID: WCMC IRB Protocol #1308014217; Sponsor Protocol # C25003; ClinicalTrials.gov #NCT01712490
50.

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: Relapsed or Refractory (not responding to previous treatment) Diffuse Large B-cell Lymphoma
  • Protocol ID: WCMC IRB #1402014746; Sponsor Protocol #PCYC-1123-CA; Clinicaltrials.gov #NCT02077166
51.

A phase 1 open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2816126 in subjects with relapsed/refractory diffuse large B cell and transformed follicular lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: GSK
  • Disease Status and/or Stage: Relapsed or Refractory (not responding to previous treatment) Diffuse Large B-cell Follicular Lymphoma
  • Protocol ID: WCMC IRB #1401014678; Sponsor Protocol #117208; Clinicaltrials.gov #NCT02082977
52.

A Phase 2 Open Label Study to Investigate the Efficacy of Autologous EBV-specific T cells for the Treatment of Patients with Aggressive Extranodal NK/T-cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Cell Medica, Inc.
  • Disease Status and/or Stage: Extranodal NK/T-cell Lymphoma
  • Protocol ID: WCMC IRB #1403014842; Sponsor Protocol #CM-2013-01; Clinicaltrials.gov # NCT01948180
53.

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed or Refractory Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Janssen Research & Development, LLC
  • Disease Status and/or Stage: Relapsed or Refractory (not responding to previous treatment) Multiple Myeloma
  • Protocol ID: WCMC IRB #1407015265; Sponsor Protocol #54767414MMY3003
54.

A Phase 1/2 Study of Pomalidomide (CC-4047®), Dexamethasone and Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Investigator
  • Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
  • Protocol ID: WCMC IRB #1306014005
55.

A Phase 1 Open-Label Study of the Safety and Efficacy of PD 0332991 (Palbociclib) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Investigator
  • Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
  • Protocol ID: WCMC IRB # 1306014004
56.

Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects

  • Study Status: Open to Enrollment
  • Sponsor: Onyx
  • Disease Status and/or Stage: Primary Refractory or Relapsed and Refractory Multiple Myeloma
  • Protocol ID: WCMC IRB # 1310014409
57.

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Pharmacyclics
  • Disease Status and/or Stage: Relapsed or Refractory Multiple Myeloma
  • Protocol ID: WCMC IRB # 1311014525
58.

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium

  • Study Status: Open to Enrollment
  • Sponsor: Celgene; Memorial Sloan Kettering Cancer Center
  • Disease Status and/or Stage: Relapsed/Refractory Multiple Myeloma
  • Protocol ID: WCMC IRB #1303013631
60.

An Open-Label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients with Relapsed and/or Refractory Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium Pharmaceuticals
  • Disease Status and/or Stage: Relapsed or refractory follicular lymphoma
61.

A Phase 2, Multi-center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant followed by Maintenance Therapy with romidepsin for the Treatment of T-cell Non-Hodgkin Lymphoma (NHL)

  • Study Status: Open to Enrollment
  • Sponsor: Memorial Sloan Kettering Cancer Center
  • Disease Status and/or Stage: Non-Hodgkin Lymphoma
62.

A Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced Hematological Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: NPM Pharma
  • Disease Status and/or Stage: Advanced hematologic malignancies
  • Protocol ID: WCMC IRB #1310014371; Sponsor Protocol #KCP-330-001; ClinicalTrials.gov #NCT01607892
63.
65.

GO27983: A Phase 1b/2 Study of GDC-0068 or GDC-0980 with Abiraterone Acetate versus Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy

  • Study Status: Open to Enrollment
  • Sponsor: Genentech
  • Disease Status and/or Stage: Metastatic or Advanced Prostate Cancer
  • Protocol ID: WCMC IRB #1210013162; Sponsor Protocol #GO27983
66.
67.

A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • Study Status: Open to Enrollment
  • Sponsor: PSMA Development Company
  • Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
  • Protocol ID: PSMA ADC 2301
68.

S1216: Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

  • Study Status: Open to Enrollment
  • Sponsor: SWOG
  • Disease Status and/or Stage: Metastatic Prostate Cancer
  • Protocol ID: S1216
69.

Gilead 0124: A Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Previously Treated Indolent non-Hodgkin Lymphoma
  • Protocol ID: Gilead 0124
70.

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

  • Study Status: Open to Enrollment
  • Sponsor: Seattle Genetics
  • Disease Status and/or Stage: Untreated Mature T-Cell Lymphoma
72.

MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagnosed Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Millennium
  • Disease Status and/or Stage: Untreated Multiple Myeloma
  • Protocol ID: C16014
73.

Analysis of Hematopoietic Progenitor Cells and Endothelial Progenitor Cells to Predict Early Relapse of Treated Non-Small-Cell Lung Cancer (NSCLC): A Pilot Study

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Non-Small Cell Lung Cancer
  • Protocol ID: WCMC IRB #1301013469
74.

A051103: A Phase 1 Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Alliance for Clinical Trials in Oncology
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: WCMC IRB #1304013838; Sponsor Protocol #A051103
75.

Alliance A051202: A Phase 1 Trial of Lenalidomide, Rituximab, and Idelalisib in Recurrent Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Alliance for Clinical Trials in Oncology
  • Disease Status and/or Stage: Recurrent Follicular non-Hodgkin Lymphoma
  • Protocol ID: WCMC IRB #1304013838; Sponsor Protocol #A051202
76.

A Phase 1b/2a Study of Romidepsin in Combination with Lenalidomide in Adults with Relapsed or Refractory Lymphomas and Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Memorial Sloan-Kettering Cancer Center
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoma and Multiple Myeloma
  • Protocol ID: WCMC IRB #1301013500
77.

A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles

  • Study Status: Open to Enrollment
  • Sponsor: Multiple Myeloma Research Foundation
  • Disease Status and/or Stage: Untreated Multiple Myeloma
79.
80.

A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX™ for the Treatment of Patients with Moderate to Severe Chronic Graft versus Host Disease (cGVHD)

  • Study Status: Open to Enrollment
  • Sponsor: Therakos
  • Disease Status and/or Stage: Moderate to Severe Graft-versus-Host Disease (GVHD)
  • Protocol ID: WCMC IRB #1205012342
81.

RDCRN 6503: Targeted Therapy of Bronchiolitis Obliterans Syndrome

  • Study Status: Open to Enrollment
  • Sponsor: NIH, GVHD Consortium
  • Disease Status and/or Stage: Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplant (HCT)
82.

RDCRN 6502: A Randomized Phase 2 Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation

  • Study Status: Open to Enrollment
  • Sponsor: NIH, GVHD Consortium
  • Disease Status and/or Stage: Cutaneous Sclerosis Post AHCT
  • Protocol ID: WCMC IRB #1206012416; Sponsor Protocol #RDCRN 6502
83.

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

  • Study Status: Open to Enrollment
  • Sponsor: Fresenius Biotech GmbH
  • Disease Status and/or Stage: Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
  • Protocol ID: IV-ATG-SCT-01
84.

A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: OncoMed
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoid Malignancies, Including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Transformed Mycosis Fungoides (MF), or Sezary Syndrome
  • Protocol ID: 52M51-001
85.

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100

  • Study Status: Open to Enrollment
  • Sponsor: Exelixis
  • Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
  • Protocol ID: XL184-307
86.

Phase 3, Multicenter, Randomized, Trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60-75 years of age with untreated high risk (secondary) AML (protocol CLTR0310-301)

  • Study Status: Open to Enrollment
  • Sponsor: Celator
  • Disease Status and/or Stage: Newly Diagnosed High Risk AML, Age 60 to 75
  • Protocol ID: WCMC IRB #1207012718
87.

Phase 3 randomized study to evaluate the substitution of Marqibo for standard vincristine sulfate injection in combination chemotherapy for subjects ≥ 60 yrs old w/ newly diagnosed ALL

  • Study Status: Open to Enrollment
  • Sponsor: Talon Therapeutics
  • Disease Status and/or Stage: Newly Diagnosed ALL, Age 60 and Older
89.

A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

  • Study Status: Open to Enrollment
  • Sponsor: Ely Lilly
  • Disease Status and/or Stage: Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)
90.

Phase 2 randomized controlled trial of pegylated interferon alpha-2b in early primary myelofibrosis

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Low or Intermediate Stage Primary Myelofibrosis (PMF)
  • Protocol ID: WCMC IRB #1202012178
91.

A Phase 2 Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic (advanced) Castrate Resistant & Neuroendocrine Prostate Cancer
  • Protocol ID: WCMC IRB #1210013164
92.
93.

A Phase 2 Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients with CLL

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated CLL
  • Protocol ID: WCMC IRB #1112012062
94.

A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Mutliple Myeloma
95.

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients

  • Study Status: Open to Enrollment
  • Sponsor: National Cord Blood Program
  • Disease Status and/or Stage: Hematologic Malignancies and Other Indications Receiving Allogeneic Hematopoieic Stem Cell Transplant
97.

A phase 3 trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL

  • Study Status: Open to Enrollment
  • Sponsor: Gynecologic Oncology Group; National Cancer Institute
  • Disease Status and/or Stage: Locally Advanced Cervical Cancer
  • Protocol ID: WCMC IRB #1203012278
98.

A Phase 1/2 Study Lenalidomide plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Relapsed/Refractory Multiple Myeloma
  • Protocol ID: WCMC IRB #0909010623
99.

An Open-Labeled, Multicenter Phase 2 Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Gastric or Gastroesophageal (GEJ) Cancer
  • Protocol ID: WCMC IRB #1208012946
100.

A Phase 2 Study of Sequential Carfilzomib, Clarithromycin, Lenalidomide, and Dexamethasone (Car-BiRD) Therapy for Subjects with Newly Diagnosed Multiple Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Newly Diagnosed Multiple Myeloma; No Previous Treatment
  • Protocol ID: WCMC IRB #1108011903
101.

A Study of Trastuzumab in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Genentech/Roche
  • Disease Status and/or Stage: Metastatic Gastric Cancer
102.

BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals

  • Study Status: Open to Enrollment
  • Sponsor: BMT-CTN
  • Disease Status and/or Stage: Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People
  • Protocol ID: BMT CTN 0903
103.

CALGB 80702: A Phase 3 Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Resected Stage 3 Colon Cancer
  • Protocol ID: WCMC IRB #1112012061; Sponsor Protocol #CALGB 80702
104.

CALGB 50801: Phase 2 Trial of Response-Adapted Therapy Based on Positron Emission of Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Bulky, Early Stage Hodgkin Lymphoma
  • Protocol ID: WCMC IRB #1306014064
105.

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

  • Study Status: Open to Enrollment
  • Sponsor: Myeloproliferative Disorders-Research Consortium
  • Disease Status and/or Stage: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
  • Protocol ID: MPD-RC 111
107.

CALGB 50901: A Phase 2 Trial of Ofatumumab (CALGB IND #112390) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: WCMC IRB #1202012205; CALGB 50901
109.

CALGB 50904: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: CALGB
  • Disease Status and/or Stage: Untreated Follicular Lymphoma
  • Protocol ID: CALGB 50904
110.

Clinical Database and Tissue Repository Collection Project for the Study of Waldenstrom's Macroglobulinemia

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
111.

A Phase 1b Safety Study of Abiraterone Acetate (JNJ 212082) and Docetaxel in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (COU-AA-206)

  • Study Status: Open to Enrollment
  • Sponsor: Cougar Biotechnology
  • Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
113.

Phase 1 Study of PD 0332991 Plus Bortezomib in Patients with Previously Treated Mantle Cell Lymphoma

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Mantle Cell Lymphoma (MCL)
114.

Treatment Decision Making in Elderly Patients with Hematological Malignancies: New Approaches to an Old Problem

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Hematological Malignancies
115.

A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

  • Study Status: Open to Enrollment
  • Sponsor: SuperGen
  • Disease Status and/or Stage: Intermediate-2 or high-risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
116.

A Randomized Phase 3 Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Cancer and Leukemia Group B, National Cancer Institute
  • Disease Status and/or Stage: High Risk, Clinically Localized Prostate Cancer
  • Protocol ID: CALGB 90203
117.

Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer using 177Lu-J591 Antibody: Dose Fractionation Regimen

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Prostate Cancer
119.

A Phase 1 Trial of Docetaxel/Prednisone plus Fractionated 177Lu-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients with Metastatic, Castrate-Resistant Prostate Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Prostate Cancer
  • Protocol ID: WCMC IRB #0812010139
120.

CALGB 90203: A Phase 3 trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy

  • Study Status: Open to Enrollment
  • Sponsor: Radiation Therapy Oncology Group, National Cancer Institute
  • Disease Status and/or Stage: Prostate Cancer After Radical Prostatectomy
  • Protocol ID: WCMC IRB #0703009081; CALGB 90203
121.

Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM)

  • Study Status: Open to Enrollment
  • Sponsor: Eli Lily & Co.
  • Disease Status and/or Stage: Unresectable, Locally Advance, Stage III Non-Small Cell Lung Cancer
122.

CALGB 140503: A Phase 3 Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2cm) Peripheral Non-Small Cell Lung Cancer

  • Study Status: Open to Enrollment
  • Sponsor: Cancer and Leukemia Group B, National Cancer Institute
  • Disease Status and/or Stage: Non-small Cell Lung Cancer
  • Protocol ID: WCMC IRB #0709009395
123.

A Randomized Double-Blinded Phase 3 Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma

  • Study Status: Open to Enrollment
  • Sponsor: Cancer and Leukemia Group B (CALGB); National Cancer Institute (NCI)
  • Disease Status and/or Stage: Advanced Transitional Cell Carcinoma
124.

A Phase 1 Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Metastatic Solid Tumor

Top of page